Australian Story - Gunnings & Stehn, page-55

This is interesting from Genscreen concerning the Trobio project that Genscreen formed way back on the 17th September 2005:

Genscreen announces the completion of the addition of Trobio project into the Genscreen portfolio and the partnership with the tropomyosin technology of Professor Peter Gunning. Professor Gunning has agreed to be a member of the Trobio Scientific Advisory Panel, along with Associate Professor Mark Smith and Dr Ricky Johnstone.
The CEO of Genscreen, Ian Dixon, announced that Trobio was an exciting addition to the existing portfolio of Genscreen; and represented a significant opportunity for a drug development project to progress towards a Phase II trial and eventual partnership with an international partner.

Genscreen obviously saw the limitations to its abilities even back then to progress the development any further than Stage 2.
The potential of the platform was known back some time and when Novogen partnered with Genscreen in late 2013 and for more than just cancer:

Established by Genscreen as a project in August 2005, the Trobio project involves the development of inhibitors of selected isoforms of tropomyosin – a novel intracellular target for cancer and other therapeutic applications.
In the Trobio project, Genscreen worked with Prof Peter Gunning and his team at the University of New South Wales. Prof Gunning is a leader in the area of the biology of a particular cytoskeleton protein isoform and its involvement in tumour growth.
This project involves the development of patentable drugs active against such protein isoforms for the treatment of cancers – including melanoma, neuroblastoma, colorectal cancer and other solid and blood tumours.


A lot of the research was already known before Novogen came onto the scene in October 2013 - Genscreen go on and say:

The aim of the partnership with Novogen is to bring a new class of anticancer drugs to the point of human trials....

Then what? or have priorities changed? - this website has not had anything updated since October 2013 - perhaps Novogen's scientist's chiefly Andrew Heaton realised pretty quickly what they had - which then makes sense why Professor Gunning was offered a directorship & Dr Justine Stehn was offered the position of ATM director at Novogen in early 2014...

http://www.genscreen.com.au/portfolio